1. High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
ClinicalTrials.gov Identifier: NCT00533949
PURPOSE: This randomized phase III trial is studying high-dose or standard-dose radiation therapy given together with chemotherapy with or without cetuximab to see how well they work in treating patients with newly diagnosed stage III non-small cell lung cancer that cannot be removed by surgery and if Overall Survival is improved.
QC
Hopital Notre Dame, Montreal
SK
Saskatoon Cancer Center, Saskatoon
Allan Blair Cancer Center, Regina
ON
Princess Margaret Hospital, Toronto
MB
Cancer Care Manitoba, Winnipeg
AB
Tom Baker Cancer center, Calgary
2. Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer
ClinicalTrials.gov Identifier: NCT01055197
This randomized phase II trial is comparing how well radiation therapy to the brain works when given with or without radiation therapy to other areas of the body in treating patients with extensive stage small cell lung cancer.
AB
Cross Cancer Institute, Edmonton
SK
Allan Blair Cancer Centre at Pasqua Hospital, Regina
3. Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer (PROCLAIM)
ClinicalTrials.gov Identifier: NCT00686959
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology
ON
Newmarket
Toronto
AB
Edmonton
QC
Montreal
4. Trial to Evaluate the Improvement in Lung Cancer Patients Receiving Radiation With or Without Brachytherapy (BRACHY)
ClinicalTrials.gov Identifier: NCT01351116
Purpose: A trial to improve the quality of life of patients with advanced non-small cell lung cancer (NSCLC) by evaluating the symptomatic improvements in lung cancer patients receiving external radiation with or without high dose internal radiation.
ON
Juravinski Cancer Center, Hamilton
5. Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Non-Small Cell Lung Cancer (NSCLC) or Metastatic Lung Tumours
ClinicalTrials.gov Identifier: NCT00351962
Purpose: Medically inoperable lung cancer or metastatic lung tumours will be treated with fractionated stereotactic radiation using a schedule of 1) 12 Gy x 4 treatments or 2) 6 Gy x 10 treatments.
AB
Tom Baker Cancer Center, Calgary
6. Phase II Trial of Consolidative Thoracic Radiotherapy for Extensive Stage Small Cell Lung Cancer
ClinicalTrials.gov Identifier: NCT00643396
Purpose: The majority of patients with small cell lung cancer have incurable extensive stage disease. The usual initial treatment for this condition is chemotherapy which produces responses in about 50-80% of patients. Despite this, the cancer usually returns. Once common body region where it re-grows is in the chest, which can cause symptoms such as shortness of breath, cough, difficulty swallowing, pain and bleeding. These symptoms can worsen a patient's quality of life and in some situation be life-threatening. In this study, we propose to give patients who have extensive stage small cell lung cancer which responds to chemotherapy radiotherapy treatments to the chest. By giving this type of radiation before the cancer has a chance to re-grow, we hope to control the disease within the chest and prevent future symptoms that it may cause if the cancer were to re-grow in the chest. Patients treated on the protocol will be checked regularly for disease control, quality of life and radiation side effects, if any.
AB
Cross Cancer Institute, Edmonton
7. Cisplatin, Etoposide, and Two Different Schedules of Radiation Therapy in Treating Patients With Limited Stage Small Cell Lung Cancer
ClinicalTrials.gov Identifier: NCT00433563
RATIONALE: Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known which schedule of radiation therapy is more effective when given together with chemotherapy in treating small cell lung cancer.
PURPOSE: This randomized phase III trial is studying two different schedules of radiation therapy to compare how well they work when given together with cisplatin and etoposide in treating patients with limited stage small cell lung cancer
ON
Princess Margaret Hospital, Toronto
8. Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
ClinicalTrials.gov Identifier: NCT00750269
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumour and cause less damage to normal tissue.
PURPOSE: This phase I/II trial is studying the side effects and best dose of stereotactic body radiation therapy and to see how well it works in treating patients with stage I non-small cell lung cancer.
ON
Princess Margaret Hospital, Toronto
9. Individual Boosting in Non-Small Cell Lung Cancer Using Hypofraction, Intensity-modulated Radiation Therapy and Respiratory Gating
ClinicalTrials.gov Identifier: NCT00690963
Patients who have inoperable non-small cell lung cancer are presently treated with chemotherapy and radiation therapy. Despite this combined approach, the vast majority of patients will have their cancer recur after treatment. A recurrence is not curable at this time. Because of the sensitivity of surrounding structures to chest irradiation, it has not been possible to give radiation doses that can cure many of these tumors. Intensity-modulated radiation therapy is a special form of radiotherapy delivery that allows doctors to reduce the amount of radiation dose to normal tissues and therefore reduce side effects. The reduction of radiation side effects may allow more radiation to be delivered to tumors, therefore improving tumor control and possibly longevity of patients. The purpose of this study is to determine whether the combination of custom designed intensity-modulated radiotherapy (based on individual tumor anatomy) with regular chepotherapy, will be safe enough to allow further intensification of radiation treatment.
AB
Cross Cancer Institute, Edmonton
10. Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
ClinicalTrials.gov Identifier: NCT00377156
This randomized phase III trial is studying stereotactic radiation therapy and whole-brain radiation therapy to see how well they work compared with stereotactic radiation therapy alone in treating patients with brain metastases.
ON
Princess Margaret Hospital, Toronto
Juravinski Cancer Center, Hamilton
AB
Tom Baker Cancer Center, Calgary
QC
CHUS-Hopital Fleurimont, Sherbrooke
11. Short Neoadjuvant Hemithoracic IMRT for MPM
ClinicalTrials.gov Identifier: NCT00797719
A Feasibility Study Evaluating Neoadjuvant Hemithoracic Intensity Modulated Radiation Therapy for Surgically Resectable Malignant Pleural Mesothelioma
ON
University Health Network, Toronto
12. Phase I/II Study of Fractionated Stereotactic Radiotherapy for Early Stage Non-Small Cell Lung Cancer
ClinicalTrials.gov Identifier: NCT00888823
A new type of treatment called stereotactic radiotherapy has recently been developed in hopes of improving the success of the treatment and improving the convenience to patients, while reducing the side effects. This study is developing stereotactic radiotherapy as a state-of-the-art treatment for lung cancer patients.
AB
Tom baker Cancer Center, Calgary
Cross Cancer Institute, Edmonton
13. Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer
ClinicalTrials.gov Identifier: NCT01336894
This randomized phase III trial is studying how well surgery with or without internal radiation therapy works compared with stereotactic body radiation therapy in treating patients with high-risk stage IA or stage IB non-small cell lung cancer.
ON
London health Sciences Center